Black M M, Zachrau R E
J Reprod Med. 1979 Jul;23(1):21-32.
As judged by in vivo and in vitro indices of cellular immunity, mammary carcinogenesis appears to be associated with immunogenic changes in the transformed cells and prognostically favorable antitumor cell-mediated immunity in the host. The prognostically favorable cell-mediated immunity appears to be directed against a component(s) which is shared by most stage 0 in situ breast cancers and the major envelope glycoprotein (gp55) of RIII murine mammary tumor virus. Progressive disease is associated with a loss of gp55-like tumor immunogenicity and/or anti-gp55 cell-mediated immunity of the host. It is appropriate that measurements of tumor immunogenicity and tumor-specific cell-mediated immunity of the host be included in the prognostic assessment and therapeutic decisions regarding individual patients. Such data are particularly pernitent to the development and evaluation of immunotherapeutic and immunoprophylactic protocols.
根据细胞免疫的体内和体外指标判断，乳腺癌的发生似乎与转化细胞中的免疫原性变化以及宿主中预后良好的抗肿瘤细胞介导免疫有关。预后良好的细胞介导免疫似乎针对大多数0期原位乳腺癌和RIII型鼠乳腺肿瘤病毒的主要包膜糖蛋白（gp55）所共有的一种或多种成分。疾病进展与宿主gp55样肿瘤免疫原性丧失和/或抗gp55细胞介导免疫丧失有关。在对个体患者的预后评估和治疗决策中纳入宿主肿瘤免疫原性和肿瘤特异性细胞介导免疫的测量是恰当的。这些数据对于免疫治疗和免疫预防方案的制定和评估尤为相关。
